AiCure

CureVac

Boehringer Ingelheim, CureVac collaborate on lung cancer immunotherapy

Thursday, September 18, 2014 01:39 PM

Boehringer Ingelheim and CureVac, a clinical stage biopharmaceutical company based in Tubingen, Germany, have announce an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer.

More... »


CureVac, Sanofi Pasteur ink agreement to develop mRNA-based prophylactic vaccine

Thursday, July 3, 2014 10:00 AM

CureVac, a German-based clinical-stage biopharmaceutical company, has inked an agreement with Sanofi Pasteur, the vaccines division of Sanofi, to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen.

More... »


CureVac collaborates with Cancer Research Institute, Ludwig Cancer Research

Monday, November 4, 2013 01:41 PM

The nonprofit Cancer Research Institute (CRI), Ludwig Cancer Research and CureVac, a clinical stage biopharmaceutical company that has developed a new class of therapies and vaccines based on messenger RNA (mRNA), will collaborate to enable clinical testing of novel cancer immunotherapy treatment options.

More... »

CureVac secures $104M in Series D financing

Wednesday, September 19, 2012 12:04 PM

CureVac, a German clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, today announced the completion of a $140 million financing round with its main investor, dievini Hopp BioTech Holding.

More... »

CureVac, Sanofi Pasteur collaborate in $33 million research project

Tuesday, November 15, 2011 11:20 AM

CureVac has signed several agreements with Sanofi Pasteur, the vaccines division of Sanofi. Under these agreements, CureVac and Sanofi Pasteur will further develop and apply CureVac’s proprietary RNActive technology platform to the development of vaccines against several infectious diseases.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs